Novel Application Of Federal Law To Scientific Fraud Worries Universities And Reinvigorates Whistleblowers

A federal law written with corrupt Department of Defense contractors in mind has become a serious concern for university administrators, while at the same time giving scientific-fraud whistleblowers new hope for success in pressing their charges. BREAKING NEW GROUND: Scientist-lawyer Eugene Dong first saw the scientific fraud aspects of the False Claims Act. The False Claims Act, also known as the Lincoln Law, was passed in 1863 and amended more than a century later, in 1986. Originally, the

Written byFranklin Hoke
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Eugene Dong BREAKING NEW GROUND: Scientist-lawyer Eugene Dong first saw the scientific fraud aspects of the False Claims Act.

While several parties firmly support or oppose the act, some feel the problems of and solution to research fraud lie not in litigation but in the way academic institutions deal with it, and respond to whistleblowers' concerns.

"The more a concerned individual feels that he or she is likely to get a fair and appropriate hearing within the institution, the more they will stay within institutional procedures," says C.K. Gunsalus, associate vice chancellor for academic affairs at the University of Illinois, which is not one of the small handful of universities targeted with a False Claims Act suit to date. "To the extent that their perception--for whatever reason--is that fair, objective, credible procedures are not available within the institution, they'll turn to this mechanism."

At stake for academic institutions is the risk of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies